Sorensen JB, Klee M, Palshof T, et al: Performance status assessment in cancer patients. An inter-observer variability study. Br J Cancer. 1993;67:773.
2.
Tsevat J, Cook F, Green ML, et al:Health values of the seriously ill. Ann Intern Med. 1995;122:514.
3.
Slevin ML, Plant H, Lynch D, et al: Who should measure quality of life, the doctor or the patient?Br J Cancer. 1988;57:109.
4.
Conti JA, Christman K: Cancer chemotherapy in the elderly. J Clin Gastroenterology. 1995;21(1): 65-71.
5.
Leslie WT: Chemotherapy in older cancer patients. Oncology. 1992;6(2suppl): 74-80.
6.
Yellen SB, Cella DF, Leslie WT: Age and clinical decision making in oncology patients. J Natl Cancer Inst. 1994;86:1766.
7.
Ganz PA, Haskell CM, Figlin RA, et al: Estimating the quality of life in a clinical trial of patients with metastatic lung cancer using the Karnofsky performance status and the functional living index-cancer. Cancer. 1988;61:649.
8.
Moinpour CM: Measuring quality of life: an emerging science. Semin Onc. 1994;21(Supp 5): 48.
9.
Cella DF: Methods and problems in measuring quality of life. Supp Care in Cancer. 1995;3:11.
10.
Moinpour C, Feigl P, Metch B, et al: Quality of life end points in cancer clinical trials: review and recommendations. J Natl Cancer Inst. 1989;81:485.
11.
Gough IR, Dalgleish LI: What value is given to quality of life assessment by health professionals considering response to palliative chemotherapy for advanced cancer?Cancer. 1991;68:220.
12.
Presant CA: Quality of life in cancer patients: who measures what?Am J Clin Oncol. 1984;7:571.
13.
Payne SA: A study of quality of life in cancer patients receiving palliative chemotherapy. Soc Sci Med. 1992;35:1505.
14.
Cella DF: Measuring quality of life in palliative care. Semin Onc. 1995;22(Supp 3): 73.
15.
Brundage M, Davidson J, Maokillop W: Trading treatment toxicity for survival in locally advanced non-small cell lung cancer. J Clin Onc. 1997;15:330-340.
16.
Ganz PA, Figlin RA, Haskell CM, et al: Supportive care versus supportive care and combination chemotherapy in metastatic non-small cell lung cancer. Cancer. 1989;63:1271.
17.
Rapp E, Pater JL, Willan A, et al: Chemotherapy can prolong survival in patients with advanced non small cell lung cancer—report of a Canadian multicenter randomized trial. J Clin Oncol. 1988;6:633.
18.
Lad TE, Nelson RB, Kiekamp V, et al:Immediate versus postponed combination chemotherapy (CAMP) for non-small cell lung cancer—a randomized trial. Cancer Treat Rep. 1981;65:973.
19.
Cornier Y, Bergerson D, LaForge J, et al: Benefits of polychemotherapy in advanced non small cell bronchogenic carcinoma. Cancer. 1982;50:845.
20.
Woods RL, Levi JA, Page J, et al: Non small cell lung cancer: a randomized comparison of chemotherapy with no chemotherapy. [Abstract]Proc Am Soc Clin Onc. 1985;4:177.
21.
Tummarello D, et al: Symptomatic Stage IV non small cell lung cancer: response, toxicity, performance status change and symptom relief in patients treated with cisplatin, vinblastin and mitomycin C. Cancer Chemotherapy and Pharmacology. 1995;35(3): 249-253.
22.
Ellis PA, et al: Symptom relief with MVP chemotherapy in advanced non-small cell lung cancer. Brit J Cancer. 1995;71(2): 336-370.
23.
Grilli R, Oxman AD, Julian JA: Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough?J Clin Oncol. 1993;11:1866.
24.
Souquet PJ, Chauvin F, Boisel JP, et al: Polychemotherapy in advanced non small cell lung cancer: a meta-analysis. Lancet. 1993;342:19.
25.
Marino R, Pampallona S, Preatoni A, et al: Chemotherapy vs supportive care in advanced non-small-cell lung cancer; results of a meta-analysis of the literature. Chest. 1994;106:861.
26.
LeLorier J, Gregoire G, Benhaddad A, et al: Discrepancies between meta-analyses and subsequent large randomized, controlled trials. NEJM. 1997;337:536-542.
27.
Ramanathan RK, Belani CP: Chemotherapy for advanced non-small cell lung cancer: Past, present and future. Sem Onc. 1997;24(4): 440-454.
28.
Fossella FV, Lee JS, Hong WK: Management strategies for recurrent non-small cell lung cancer. Sem Onc. 1997;24(4): 455-462.
29.
Moore MJ, Osoba D, et al: Use of palliative and points to evaluate the effects of mitoxantrone and low dose prednisone in patients with hormonally resistant prostate cancer. J Clin Onc. 1994;12(4): 689-694.
30.
DeLeo A, Bajetta E, et al: Epirubicin plus medroxyprogesterone versus second-line treatment of advanced prostatic cancer. Am J of Clin Onc. 1995;18(3): 239-244.
31.
Tannock IF, Osoba D, et al: Chemotherapy with mitoxantrone prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Onc. 1996;14(6): 1756-1764.
32.
Glimelius B, Hoffman R, et al: Cost-effectiveness of palliative chemotherapy in advanced gastrointestinal cancer. Annals of Oncology. 1995;6(3): 267-274.
33.
Jager, et al: Combination 5FU FA and alpha interferon 2B in advanced gastric cancer: results of a phase II trial. Annals of Oncology. 1995;6(2): 153-156.
34.
Burris HA, Moore JM, Andersen J, et al: Improvements in survival and clinical benefit with Gencitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Onc. 1997: 15(6): 2403-2413.
35.
Dombernowsky P, Hansen H: Combination chemotherapy in the management of superior vena caval obstruction in small-cell anaplastic carcinoma of the lung. Acta Med Scand. 1978;204:513.
36.
Hayes A, Thompson EI, Hvizdala E, et al: Chemotherapy as an alternative to laminectomy and radiation in the management of epidural tumor. J Pediatr. 1984;104:221.
37.
Sinoff LL, Blumshon A: Spinal cord compression in myelomatosis: response to chemotherapy alone. Eur J Cancer Clin Oncol. 1989;25:197.
38.
Goldie JH, Coldman AJ: A mathematic model for relating to drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treatment Reports. 1979;63:1727.
39.
Goldie JH, Coldman AJ: Application of theoretic models to chemotherapy protocol design. Cancer Treatment Reports. 1986;70:127.
40.
Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial. J Clin Oncol. 1992;10:904.
41.
Glimelius B, Graf W, Hoffman K, et al: General condition of asymptomatic patients with advanced colorectal cancer receiving palliative chemotherapy. Acta Oncol. 1992;31:645.
42.
Lung Cancer Working Party. Survival, adverse reactions and quality of life during combination chemotherapy compared with selective palliative treatment for small cell lung cancer. Respir Med. 1989;83:51.
43.
Horning SJ, Rosenberg SA: The natural history of initially untreated low-grade non-Hodgkin’s lymphoma. NEJM. 1984;311:1471-1475.
44.
O’Brien ME, Easterbrook P, Powell J, et al: The natural history of low grade non-Hodgkin’s lymphoma and the impact of a no initial treatment policy on survival. Q J Med. 1991;80:651-660.
45.
Young RC, Longo DL, Glatstein E, et al.The treatment of indolent lymphomas: watchful waiting v. aggressive combined modality treatment. Semin Hematol. 1988;25(suppl): 11-16.
46.
Hoppe RT, Kushlan P, Kaplan HS, et al.The treatment of advanced stage favorable histology non-Hodgkin’s lymphoma: A preliminary report of a randomized trial comparing single agent chemotherapy, combination chemotherapy, and whole body irradiation. Blood. 1981;58:592-598.
47.
Yellen SB, Cella DF: Someone to live for: social well-being, parenthood status, and decision-making in oncology. J Clin Oncol. 1995;13:1255.
48.
Siminoff LA, Fetting JH: Factors affecting treatment decisions for a life-threatening illness: the case of medical treatment of breast cancer. Soc Sci Med. 1991;32:813.
49.
Coates A, Gebski V, Bishop JF, et al: Improving the quality of life during chemotherapy for advanced breast cancer. NEJM. 1987;317:1490.
50.
Muss HB, Case D, Richards F, et al: Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. NEJM. 1991;325:1342.
51.
Harris AL, Cantwell BM, Carmichael J, et al: Comparison of short term and continuous chemotherapy (mitoxantrone) for advanced breast cancer. Lancet. 1990;335:186.
52.
Smalley RV, Lefante J, Bartelucci A, et al: A comparison of cyclophosphamide, adriamycin, and 5-fluorouricil and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine and prednisone in patients with advanced breast cancer. Breast Cancer Res Treat. 1983;3:209.
53.
Levin DN, Cleland CS, Dar R: Public attitudes toward cancer pain. Cancer. 1985;56:2337-2339.
54.
Slevin ML, Stubbs L, Plant HJ, et al:Attitudes to chemotherapy: comparing view of patients with those of doctors, nurses, and general public. Br Med J. 1990;300:1458.
55.
Coates A, Abraham S, Kaye SB, et al: On the receiving end—patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol. 1983;19:203.
56.
Dougherty C, Ratain M, Grochowski E, et al:Perceptions of cancer patients and their physicians involved in phase I trials. J Clin Oncol. 1995;13:1062.
57.
VonHoff DD, Turner J: Response rates, duration of response, and dose response effects in phase I studies of antineoplastics. Invest New Drugs. 1991;9:115.
58.
Estey E, Hoth D, Wittes R, et al:Therapeutic response in phase I trials of anti-neoplastic agents. Cancer Treat Rep. 1986;70:1105.
59.
Whippen DA, Canellos GP: Burnout syndrome in the practice of oncology: results of a random survey of 1,000 oncologists. J Clin Oncol. 1991;9:1916.
60.
Holland JF, Frei E, Kufe DW, et al (eds.): In Cancer Medicine. Principles of medical oncology. 4th ed. CITY, Williams & Wilkens, 1997: 761.
